you can view training videos on Dupixent’s manufacturer website. There are also injection instructions in Dupixent’s prescribing information. You can also ask your pharmacist or doctor if you ...

An archive and transcript of this call will be available on the Regeneron Investor Relations website shortly after ... primarily, Dupixent, Libtayo, and EYLEA and EYLEA HD. 2024 was also a year ...

Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large ...

French drugmaker Sanofi reported a fourth-quarter profit that came in-line with analysts' estimates on Thursday, and said it would buy back 5 billion euros ($5.21 billion) in shares this year as it ...

Dry Skin Cream, Lotion, and Ointment MarketThe global dry skin cream, lotion, and ointment market is on the cusp of substantial expansion, according to recent market analysis. The industry is ...

This includes medicated creams and pills, dupilumab (Dupixent) injections ... The information on this website may assist you in making personal decisions about insurance, but it is not intended ...

All the necessary information is either in 20-Fs/10-Ks or on the FDA website, namely in the "Orange ... So, sales of Dupixent (dupilumab), an IL-4/IL-13 inhibitor, in the third quarter of 2024 ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...